速递｜欧盟放大招：司美格鲁肽7.2mg获批，肥胖患者平均减重20.7%再抬天花板

Core Viewpoint - The European Commission has approved a new higher dosage of Wegovy (semaglutide injection) at 7.2 mg for long-term weight management in obese adults, providing a stronger option for patients who do not achieve sufficient weight loss with the standard 2.4 mg dosage [5][10]. Summary by Sections Approval and Dosage Strategy - The approval of the 7.2 mg dosage is based on positive recommendations from the EMA and data from the STEP UP trial, indicating that this dosage is not merely an increase but offers an option for patients with lower weight loss ceilings [5]. - The 7.2 mg dosage is administered through three injections of 2.4 mg each week, maintaining the same frequency but increasing the complexity of administration [7]. Efficacy and Weight Loss Outcomes - In the STEP UP study, the average weight loss for the 7.2 mg group was 20.7%, compared to 17.5% for the 2.4 mg group and 2.4% for the placebo [7]. - The 7.2 mg dosage is positioned as an accelerator for patients aiming for more significant weight loss rather than a universal entry point for all patients [8]. Treatment Adherence and Real-World Data - When considering treatment adherence, the 7.2 mg group showed an 18.7% weight loss, while the control group had a 3.9% loss, with 90.7% of the 7.2 mg group achieving at least 5% weight loss [8]. - This data reflects real-world clinical variability, which is crucial for understanding the potential outcomes in broader public health contexts [8]. Safety and Tolerability - The primary adverse events for the 7.2 mg dosage remain gastrointestinal reactions, with a higher discontinuation rate due to these effects compared to the 2.4 mg group [9]. - Balancing stronger weight loss with sustainable medication use will depend on physicians' ability to manage patient profiles and side effects [9]. Market Implications - The approval of the 7.2 mg dosage expands Wegovy's dosage options in Europe, creating a more comprehensive treatment pathway for patients requiring significant weight loss [10]. - The structured dosage approach from initial low doses to higher maintenance doses allows for tailored treatment plans for patients who have been on the 2.4 mg dosage for at least four weeks [10].